Evidence map›Paper›PMID 42480986›Full record

ArticleACS infectious diseases2026

Multipronged Cell Wall-Targeting Converts Ineffective Antibiotics into a Potent Regimen against Mycobacterium abscessus.

Carmen J E Pee, May Delos Santos, Kevin Pethe

Abstract read
In one paragraph

Article in ACS infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Carmen J E PeeLee Kong Chian School of Medicine, Nanyang Technological University, Singapore636921, Singapore.ORCID 0000-0002-0464-1660
May Delos SantosAntimicrobial Resistance (AMR) IRG, Singapore-MIT Alliance for Research and Technology, 1 CREATE Way, Singapore138602, Singapore.
Kevin PetheLee Kong Chian School of Medicine, Nanyang Technological University, Singapore636921, Singapore.

Funding

Ministry of Education - Singapore RT0120Nanyang Technological University NANational Medical Research Council OFIRG24jan-0064Singapore Therapeutics Development Review H22G0a0003
6 · The paper itself

Abstract

Mycobacterium abscessus is an intrinsically drug-resistant pathogen responsible for chronic lung infections that are notoriously difficult to cure. Its complex, multilayered cell wall limits drug penetration and underlies the poor efficacy of most antibiotics. Here, we show that targeting multiple components of cell wall biosynthesis simultaneously can convert otherwise inactive agents into potent, bactericidal combinations. Pairing glycopeptides with β-lactams led to synergistic killing, while inclusion of ethambutol further enhances potency. Mechanistic studies indicated that the combinations act through cumulative weakening of the cell envelope. Concomitant inhibition of peptidoglycan and arabinogalactan or lipoarabinomannan synthesis caused extensive ATP leakage and improved access of vancomycin to its targets, consistent with additive structural damage. This multilayered disruption rendered the cell wall unable to maintain integrity. The triple combination of teicoplanin, cefoxitin and ethambutol also decreased lung bacterial loads in mice infected with M. abscessus. These findings establish that intrinsic antibiotic resistance in M. abscessus can be overcome by coordinated interference with cell wall biogenesis using clinically available antibiotics. This strategy provides a mechanistic framework for rational repurposing of existing drugs to treat nontuberculous mycobacterial infections for which new therapies are urgently needed.

Indexed as

Anti-Bacterial AgentsCell WallMycobacterium abscessusMycobacterium Infections, NontuberculousAnimalsbeta-LactamsDrug SynergismEthambutolGlycopeptidesMiceMicrobial Sensitivity TestsPeptidoglycanAnti-Bacterial Agentsbeta-LactamsEthambutolGlycopeptidesPeptidoglycanantimicrobial resistancecell wallethambutolGlycopeptideNTMβ-lactam

Identifiers

PMID42480986
PMCPMC13488445

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.